In contrast, the meta-analysis by Gong et al. published in 2021, that included 1922 patients from 13 studies in a mixed population cohort (Japan, China, North America, Bangladesh, Korea, Italy, Egypt, Indonesia, and Myanmar) found an association between the GSTP1 rs1695 AG/GG genotypes (G vs. AA) and a higher risk of gastrointestinal toxicity (RR= 1.61; 95%CI = 1.18–2.19; p = 0.003) and infection (RR = 1.57; 95%CI = 1.00–2.48; p = 0.05) in patients with cancer and autoimmune diseases undergoing cyclophosphamide treatment. This evidence concerns the gene GSTP1 and autoimmune disease.